We would love to hear your thoughts about our site and services, please take our survey here.
Just listen to the presentation if you haven’t already.
Revenues….
Great Traction….
FDA registration….
Great partners….
Help get the product into the US……
NICE recommendation ties down TRUSTS to use the test
Further designs for future tests……
Proper commercial traction…..
Pushing to sell products around the Globe…..
First to Market!!!
This was over 200p in 2020, and as I mentioned yesterday, when I started researching the Company, the assent to 200p was almost vertical from a base of 10p.
It can move extraordinarily quickly.
Indeed, Momentum is building here again……
Mm’s seem to have sorted out liquidity and buying now available at 2.49p.
Current cash of over £8 Million & MCap £4M.
Interesting to see CEO & CFO share options granted at 14p, these were RNS’s recently on March 5th so there’s plenty of confidence for a good uplift.
Should have read:
“It would be good to see recent big buys as Director Buys”
Apologies, My previous post suggested they were, which was misleading.
Yesterday, Big order being filled, they’ll take 500,000 no problem but NT for 500.
100K NT is now 2.9p, so MM’s just want sellers.
Good to see recent big buys as Director Buys.
1,080,000 Buy at 2.3749p plus another 500K buy an hour earlier.
NT to buy now and 2.8p for 100k.
Think they’d struggle to delist with the quantum raised by institutional investors that remain on the significant shareholder base.
Furthermore, the BOD are clearly confident in the Company with the RNS announcement on the 05th March 2024 granting 2 Million share options to the CEO & CFO at an exercise price of 14p.
This is an illiquid stock that moves quickly in either direction, and a seller has brought it down rapidly.
Could be a big rebound on evidence of traction in their target market.
Plus the have a cash pile of $9.61M by my estimates, given cash of $15.81M on June 30th 2023 ( HY) and an average monthly burn of 680K.
Cash runway into 2025 not including revenues.
Seems to have fallen a very long way.
Current MCap £3M.
“Singer Capital Markets is delighted to have acted as Nominated Adviser and Sole Bookrunner to Trellus Health (TRLS.LN) on its AIM IPO raising £28.5 million in May 2021; with a market capitalisation of £64.6 million on admission.”
Whilst it seems we still have a seller in our midst, it should be noted, as per the RNS dated 8th March 2024, that Rathbones continues to build a significant holding, now 18.47%, over 90 Million Shares.
From the Rathbones website:
“Rathbones intends to build wealth for individuals, families & institutions. Not just a wealth, but enduring Value”.